ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Celgene

Status: Completed

Conditions: Lymphoma, T-Cell, Peripheral

Treatments: Drug: Istodax

Study type: Observational

Funder types: Industry

Identifiers

NCT03742921

ROMI-PTCL-001

U1111-1222-2854 (Registry Identifier)

Details and patient eligibility

About

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax.

1. Planned registration period 4 years
2. Planned surveillance period 5 years and 6 months

Enrollment: 150 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time.

Exclusion criteria

N/A

Trial design

150 participants in 1 patient group

Relapsed or Refractory T-Cell Lymphoma patients with Istodax

Description:

Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance

Treatment:

Drug: Istodax